Lifeboat Foundation

Circulating branched-chain amino acids (BCAAs) are elevated in obesity and diabetes, and recent studies support a causal role for BCAAs in insulin resistance and defective glycemic control. The physiological mechanisms underlying BCAA regulation are poorly understood. Here we show that insulin signaling in the mediobasal hypothalamus (MBH) of rats is mandatory for lowering plasma BCAAs, most probably by inducing hepatic BCAA catabolism. Insulin receptor deletion only in agouti-related protein (AgRP)–expressing neurons (AgRP neurons) in the MBH impaired hepatic BCAA breakdown and suppression of plasma BCAAs during hyperinsulinemic clamps in mice. In support of this, chemogenetic stimulation of AgRP neurons in the absence of food significantly raised plasma BCAAs and impaired hepatic BCAA degradation.

2 things I like here. 1. Aubrey says not only does he think the first person to live to 1000 may be alive today but that they are already middle aged(Like me!). 2. In 15 years we might give a 70 year old treatment that will not make them 20 again, but perhaps it will make them 40. then by the time they hit 70 again the treatments available will be even better.

Dr. Aubrey de Grey is a biomedical gerontologist based in Mountain View, California, USA, and is the Chief Science Officer of SENS Research Foundation, a California-based 501©(3) biomedical research charity that performs and funds laboratory research dedicated to combating aging. In addition, he is Editor-in-Chief of Rejuvenation Research, the world’s highest-impact peer-reviewed journal focused on intervention in aging. He received his BA in computer science and Ph.D. in biology from the University of Cambridge. His research interests encompass the characterization of all the types of self-inflicted cellular and molecular damage that constitute mammalian aging and the design of interventions to repair and/or obviate that damage. Dr. de Grey is a Fellow of both the Gerontological Society of America and the American Aging Association, and sits on the editorial and scientific advisory boards of numerous journals and organizations. He is a highly sought-after speaker who gives 40–50 invited talks per year at scientific conferences, universities, companies in areas ranging from pharma to life insurance, and to the public. Topics Discussed: Brief overview of SENS
- Why try to end aging?
- How soon do you think we will end aging?
- What role does rejuvenation biotech play in the COVID-19 pandemic? How would regenerative medicine help us better cope with the pandemic?
- How are you implementing the techniques you research in your own life?
- Which breakthrough are you most proud of?Aubrey’s Links: LinkedIn: https://www.linkedin.com/in/aubrey-de-grey-24260b/
Personal Website: https://www.sens.org/
Company Website: https://www.mfoundation.org/
Twitter: https://twitter.com/aubreydegreyListen to the audio version at: https://www.buzzsprout.com/765170/7722976-dr-aubrey-de-grey-…e-agingYou can listen to the audio and read the transcript here: https://podcast.boomerliving.tv/dr-aubrey-de-grey-what-cause…-aging/You can listen to many other audio podcasts on our website and Apple Podcasts: https://podcast.boomerliving.tv/
https://podcasts.apple.com/us/podcast/boomer-living-senior-l…1455929808

The detailed physical processes and pathways involved in the transmission of COVID-19 are still not well understood. Researchers decided to use advanced computational fluid dynamics tools on supercomputers to deepen understanding of transmission and provide a quantitative assessment of how different environmental factors influence transmission pathways and airborne infection risk.

SARS-CoV-2 mutations similar to those in the B1.1.7 UK variant could arise in cases of chronic infection, where treatment over an extended period can provide the virus multiple opportunities to evolve, say scientists.

Writing in Nature, a team led by Cambridge researchers report how they were able to observe SARS-CoV-2 mutating in the case of an immunocompromised patient treated with convalescent plasma. In particular, they saw the emergence of a key mutation also seen in the new variant that led to the UK being forced once again into strict lockdown, though there is no suggestion that the variant originated from this patient.

Using a synthetic version of the virus Spike protein created in the lab, the team showed that specific changes to its genetic code — the mutation seen in the B1.1.7 variant — made the virus twice as infectious on cells as the more common strain.

Shoma Abhyankar is one of millions of Indians who turned to electric and electronic appliances during the Covid-19 pandemic to fill a housework gap left by limiting contact with domestic workers. The takeover by gadgets and machines could have lasting consequences, changing the face of domestic work across the nation.

Many Indian families started doing their own household chores when coronavirus lockdowns began, causing a sales boom for appliances and leaving domestic workers unemployed.

August 2020… “As Covid-19 continues to take lives on a daily basis, the search is ongoing for solutions that might prevent, cure or treat the deadly disease. In recent months, some have pointed to cannabis as a possible treatment for severe cases of the Covid-19 — pointing specifically towards the cannabinoid CBD, one of cannabis’ main chemical ingredients. And some research has suggested that this cannabinoid could be helpful. Now, a synthetic cannabinoid drug, ARDS-003, has been given approval by the FDA to begin phase-1 clinical trials. ARDS-003 is an injectable drug designed to help with acute respiratory distress syndrome (ARDS), a serious syndrome that occurs in severe cases of the novel coronavirus. This syndrome can be triggered during a cytokine storm, a dangerous over-elevation of cytokines. Cytokines are proteins which signal the body to produce more inflammation. While inflammation is a normal and healthy part of immune responses, when too much of it is produced, it can lead to serious and deadly problems like organ failure and ARDS. ”.

Dr. Ann Aerts MD, Head of the Novartis Foundation and Member of the US National Academies of Medicine Commission on Healthy Longevity.

Dr. Ann Aerts, M.D. is Head of the Novartis Foundation, an organization committed to transforming the health of low-income populations, by leveraging the power of data, digital technology and artificial intelligence (AI) to re-imagine health and care around the world.

Continue reading “Dr. Ann Aerts, MD — Novartis Foundation — Transforming The Health Of Low-Income Populations Globally” »

Summary: A new machine-learning algorithm which videos of echocardiograms is able to accurately predict patients who will die within a year.

Source: Geisinger Health System

Tracking recent mutations, variants and lineages.